Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 3 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Recs

0
Player Avatar elliotyoung (< 20) Submitted: 5/2/2010 12:53:39 AM : Outperform Start Price: $52.70 BIIB Score: +138.16

Buy. Good momentum and PEG.

Featured Broker Partners


Advertisement